Public benefit corporation (PBC) founded by the Multidisciplinary Association for Psychedelic Studies (MAPS) focused on transforming mental healthcare Lykos Therapeutics (Lykos) announced on Thursday that it has named Michael Mullette as its interim CEO.

Mullette is replace Amy Emerson, who is stepping down as chief executive officer (CEO). Emerson is transitioning into a senior advisor role through the end of the year and will serve as an Observer on the Lykos Board.

The interim CEO has over two decades of experience in the pharmaceutical industry, most recently leading North America for Moderna. He has served for around 20 years with Sanofi, where he held management and leadership roles across the US, France, Japan, Australia, and Canada, including as GM and Country Chair of Sanofi Canada and as GM of Sanofi Pasteur in Japan.

Emerson said, 'We founded Lykos with a deep belief in the need for innovation in mental health, and I am deeply grateful for the privilege of leading our efforts. While we are not at the finish line, the past decade of progress has been monumental. Mike has been an outstanding partner and is well prepared to step in and lead our next steps. I know he will continue to pursue Lykos' mission of helping patients with unwavering dedication and resolve.'